Skip to content

Usage of cookies

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our privacy policy.

UK hospitals to harness the power of AI gut-imaging to aid treatment of Crohn’s Disease

UK hospitals to harness the power of AI gut-imaging to aid treatment of Crohn’s Disease 

  • £1.2M National Institute for Health and Care Research (NIHR) funding will see more than 10 UK NHS hospitals (3400 patients) utilising GIQuant  to improve analysis and management of Crohn’s Disease
  • Inflammatory Bowel Disease (IBD) costs the NHS £720 million a year, with relapses accounting for up to half the total cost (1)
  • Approximately 115,000 people in the UK are living with Crohn’s disease
  • World IBD Day, on May 19th, unites people worldwide in their fight against Crohn’s disease and ulcerative colitis

 

LONDON, UK. 17TH MAY 2022Today, Motilent, the first company to specialise in the assessment of digestive diseases using AI medical image analysis, announces a total of  £1.2M National Institute for Health and Care Research (NIHR) funding to develop and roll out its  technology into more than 10 UK hospitals, including UCLH, Nottingham University Hospital and Frimley Park Hospital.

Crohn’s Disease is a painful, debilitating inflammatory bowel condition that affects 115,000 people in the UK, with 33% diagnosed before age 21. (2)  Currently, anti-inflammatory medications are the standard of care. However, for the 40% who do not experience inflammatory symptoms, these medications are ineffective and can cause severe side effects, as well as costing the UK economy over £280 million every year. (3)

Currently, 69% of the UK population experiences persistent gut issues, contributing to 1 in 8 deaths in the UK. (4) As a result, innovation in care for those affected by these conditions is a critical focus for the NIHR. Through its Invention for Innovation (i4i) Programme, the NIHR has invested £14M into ‘Oral and Gastrointestinal (GI)’ research – supporting the development of medical technologies by helping them to make the jump from concept to clinic, and enhance patient treatment and recovery. 

Building on its initial £685k investment, NIHR have awarded an additional £562k to Motilent to support the rollout of GIQuant to NHS trusts across the UK. The investment is the latest NIHR research grant awarded to Motilent – prior awards have focused on accelerating the development of GIQuant, by evaluating Crohn’s Disease activity with MRI and predicting treatment response in Crohn’s patients

 

Improving clinical confidence in Crohn’s Disease management

Motilent’s FDA cleared and CE Marked post-processing software, GIQuant, is already used by several UK health services including Great Ormond Street Hospital, and complements standard magnetic resonance imaging (MRI) scans to measure and track movement of the intestine. This measure of motility is often affected by GI disease inflammation – the more inflamed the bowel, the less it moves – and therefore provides insights into disease progression and treatment response. 

With an initial focus on Crohn’s disease, GIQuant aids physicians in advanced image assessment, providing data-led insights to monitor therapeutic response and allow for more informed clinical treatment decisions. This extra layer of objective data, collected non-invasively, can help physicians identify ineffective therapies faster, and speed up patient treatment journeys. 

 

Real world evidence – real world impacts

The NIHR funding will support a retrospective study on historic MRI scans, focused on training, and a prospective component across more than 3400 patients, in collaboration with clinicians and over 10 UK hospitals, collecting real world evidence to drive changes in the clinical management of Crohn’s Disease. The research will also explore the reduction in use of intravenous (IV) contrast dyes, which can cause severe side effects (5,6), and may offer potential NHS cost savings of millions each year through a combination of efficiency and efficacy improvements.

Motilent CEO Alex Menys commented: “One of the first questions we are asked is ‘who else is using GIQuant?’ and through this grant we have an opportunity to really drive the tech into a lot of different types of hospitals and give the clinical community the time (and resource) to see how GIQuant can fit their workflows. This of course builds on regulatory clearance and a large number of published papers, but there is no substitution for hands on use.”

Raffaella Roncone, Head of Innovation and Enterprises for NIHR’s i4i programme, said: “Motilent’s innovative work to find better ways to see inside the gut and monitor how treatment is working really has the potential to improve patients’ lives, and make the healthcare system more effective. We’re really excited to see how this technology develops and proud to be supporting this research.” 

Gordon Moran, Clinical Associate Professor at The University of Nottingham, commented: “This is an excellent piece of work from Motilent. With the new treat-to-target approach in inflammatory bowel disease it is imperative to have the right target which is accurate and affordable. This will allow us to treat patients better so that they can achieve a better quality of life. GIQuant definitely ticks all the boxes needed.”

For further information, please contact:

Belle Taylor | [email protected]

  • Alex Menys, Motilent CEO, and Nigel Horwood, Crohn’s patient advocate, are available for comment. Please email Belle Taylor (above) to arrange.

About Motilent:

Motilent is a technology startup on a mission to change the way we see the gut. Specialising in the assessment of digestive diseases using medical image analysis, their main focus area is Crohn’s Disease but also includes Irritable Bowel Syndrome (IBS) and Gastroparesis. Motilent’s first product GIQuant aims to help clinicians to identify earlier when patients stop responding to immunotherapy.

About National Institute for Health and Care Research (NIHR):

The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by:

  • Funding high quality, timely research that benefits the NHS, public health and social care;
  • Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services;
  • Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research;
  • Attracting, training and supporting the best researchers to tackle complex health and social care challenges;
  • Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system;
  • Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries.

NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK Aid from the UK government.

AI gut-imaging software takes on the US with FDA clearance and national hospital partnership

 

AI gut-imaging software takes on the US with FDA clearance and national hospital partnership

 

  • Motilent’s clinically-validated AI software has received 510k clearance from the US FDA
  • Currently, 62 million people in the US are diagnosed with a digestive disorder annually, causing an ever-growing burden on healthcare services globally
  • Almost $136BN is spent on GI therapies annually but some drugs, e.g. those used in Inflammatory Bowel Disease, have a 60% failure rate within 1 year. It can take months or years to confirm if a therapy is no longer working for a patient.
  • New collaboration with AI-powered solutions provider Nuance Communications will allow US healthcare clinics using innovative GIQuant software to accurately measure intestinal motility and treatment response using AI medical image analysis

 

LONDON, UK. 23/11/21:  Today, Motilent, the first company to specialise in the assessment of digestive diseases using AI medical image analysis, announces FDA 510K clearance in the USA. The rollout of this technology will be in partnership with Nuance AI solutions.

 

Launched in 2013 by King’s College London and University College London (UCL) alumnus Dr. Alex Menys, Motilent was created to support the 62 million people1 affected by digestive diseases in the US, and ultimately help get patients on the right treatment more quickly.

 

The post-processing software, GIQuant, already used in UK institutions including Great Ormond Street Hospital, works alongside standard magnetic resonance imaging (MRI) scans to measure and track movement of the intestine. This measure of intestinal movement, known as ‘motility’, is often affected by gastrointestinal (GI) disease activity, and thus provides insights into disease progression. 

 

Spotting treatment failure in Crohn’s Disease: With an initial focus on Crohn’s disease, GIQuant aids physicians in advanced image assessment: providing data led insights to monitor therapeutic response and allow for more informed clinical treatment decisions. This extra layer of objective data – collected non-invasively – can help physicians take patients off ineffective therapies faster, and speeds up patient treatment journeys. 

 

The new FDA 510k clearance [search K211356] gives Motilent the greenlight to deploy GIQuant across healthcare providers in the US. Supporting the move into the US healthcare market, the company has also announced a new partnership with AI patient-care software provider Nuance. 

 

Used by 90% of hospitals, 10,000 healthcare organisations worldwide,  and 80% of US radiologists, Nuance’s AI‑powered solutions capture 300 million patient journeys each year and apply real-time intelligence to support clinical decision-making. Collaborating with Nuance, GIQuant will equip clinicians, radiologists and care teams with new motility data and a suite of actionable insights to help monitor, understand, and ultimately improve clinical quality and patient safety. 

 

Motilent CEO Alex Menys comments: “For me, the digestive tract has always been an enigmatic but crucial system that influences how we feel, what we think and often how we act. Across a range of diseases, symptoms like abdominal pain, constipation and nausea cause a huge amount of distress and impact on quality of life. To date, our options for analysing the gut have been limited – hindering basic research, drug development and ultimately effective patient treatment. With FDA clearance, our first product GIQuant can be used in combination with routine MRI to easily evaluate gastrointestinal function. I’m hugely proud of the Motilent team and excited by the potential this technology has to improve the management of digestive disease.”

 

Peter Ellis, Chairman of Motilent says: “FDA clearance is an important step for Motilent as we move to the US market. Through our partnership with Nuance, and via our own direct sales capabilities, we will have extensive market access, ensuring more US patients have access to Motilent’s technology. This is an incredibly exciting milestone for us on our mission to get every patient with digestive disease on the right treatment, at the right time.”

 

To mark their launch in the US, Motilent will be exhibiting for the first time at RSNA 2021, the Radiological Society of North America’s annual conference, taking place 28th November-1st December 2021. The team will showcase their technologies (booth 5158) and discuss GIQuant in real world settings, including initial experiences and findings from a year’s use at Frimley Park Hospital NHS Foundation Trust.

 

To find out more about Motilent, please visit: https://www.motilent.co.uk/ 

 

– ENDS –

Notes to editors:

 

Motilent will be exhibiting at RSNA 2021 (28th November-1st December), at booth 5158.

Please arrange a meeting, or one-to-one demo, with the team using this link: https://calendly.com/motilent/1-to-1-demo-at-rsna-2021?month=2021-11

 

For further information, please contact:

Belle Taylor | [email protected]

 

  • Alex Menys, Motilent CEO, is available for comment. Please email Belle Taylor (above) to arrange.

 

About Motilent

Motilent is a technology startup on a mission to change the way we see the gut. Specialising in the assessment of digestive diseases using medical image analysis, their main focus areas include Crohn’s Disease, Irritable Bowel Syndrome (IBS) and Gastroparesis. Motilent’s first product GIQuant aims to help clinicians to identify earlier when patients stop responding to immunotherapy.

Motilent & Partners Receive Prestigious UKRI Funding

  • Crohn’s Disease is a chronic inflammatory condition of the intestine affecting people of all ages.
  • There is an urgent need for technology to guide the use of powerful and expensive anti-inflammatory medications.
  • Motilent has been awarded  a prestigious UKRI grant to tackle this challenge.

About the project

Motilent has been awarded a UKRI grant to improve the way Crohn’s Disease is managed in adults and children.

A total of seven projects led by many of the UK’s leading institutions were funded as part of the £16 million call designed to enable the development of disruptive technologies to improve outcomes in chronic and challenging disease areas.  

Working with Great Ormond Street Hospital, University College London (UCL), University of Nottingham (UoN) and IBDrelief, Motilent will develop an improved method of assessing medical imaging data from MRIs of Crohn’s disease patients, while incorporating a range of time and cost saving advances for a routine MRI test.

Approximately 180,000 people live with Crohn’s disease in the UK and there is no cure. Flare ups are managed with powerful but expensive immunosuppressive medications, which have a high failure rate. This project will help ensure the right patients are receiving the right medications at the right time for them.

This image shows three types of MRI scan of the same patient with severe Crohn’s Disease. The blue box represents the area of disease (thickened bowel on the left, low motility in the middle and bright inflamed bowel on the right). The blue circle shows normal bowel. These images are currently interpreted subjectively by Radiologists. The goal of the project is to quantitatively assess the data produced by MRI so smaller changes can be detected to fine tune patient treatment.

 

What the project partners say

Alex Menys, CEO Motilent: “This project has been a long time in the works and brings together a fantastic and dedicated team with the ability to deliver this exciting programme of work. We’re going to be developing a tool for the radiologist to generate an objective score for Crohn’s Disease activity based on well validated parameters that are currently too time consuming to perform clinically.”

Professor Stuart Taylor, Consultant Radiologist, UCL:MRI plays an very important role in diagnosing Crohn’s disease as well as treatment planning and monitoring. Interpretation is relatively subjective and time consuming. The software developed in this project will increase both the accuracy and speed of MRI interpretation which will be a significant advance.”

Dr Tom Watson, Consultant Paediatric Radiologist, GOSH: “I am routinely asked to image children as young as 4 with Crohn’s Disease. Imaging the bowel in children can be extremely challenging. An MRI scanner is an intimidating place for an adult let alone a child and on top of that, children need to be still for upwards of 30 minutes using conventional scanning protocols. These protocols often require injection of drugs to highlight areas of inflammation. This requires needles which increases the anxiety for our children with Crohn’s. For me, high quality, high speed imaging without the need for injections would be a huge leap forward. At GOSH we’ll be taking the latest advances in adult imaging and analysis and ensuring they’re relevant to our paediatric population.”

Dr. Gordon Moran, Consultant Gastroenterologist, UoN:This project is going to help me get a quantitative score for Crohn’s Disease activity which especially in the small bowel is hugely important for assessing treatment response with powerful expensive medications. We’re also going to be able to tie our existing work in fibrosis imaging at UoN into a new protocol expanding the clinical utility of the technique.”

Seb Tucknott, CEO of IBDrelief, said: “This project is really exciting and could have some big benefits for patients with Crohn’s disease in the small bowel, helping them to receive more targeted treatments in a more timely fashion. At IBDrelief we are passionate about ensuring that patients are involved in every stage of research and development to achieve the best outcomes possible, so we are delighted to be working with Motilent and partners to make sure this project helps make a big difference to patients as well as clinical teams.”

What happens next?

This project is now well underway and we’ll up providing regular updates. Follow us on Linkedin or Twitter or email us at [email protected]

Our partners can be found at:

UCL Centre for Medical Imaging

University of Nottingham BRC

IBDrelief

Great Ormond Street Hospital

Motilent appoints Laurence Bourn as Chief Technical Officer

We are delighted to announce that Laurence Bourn has joined the Motilent team as Chief Technical Officer. Laurence started working with Motilent in August 2019 and will lead the growth of the Company’s technical operations as it enters the clinic.


Laurence has 20 years of commercial experience within the medical device industry. He began as a software engineer in the early days of Voxar in Edinburgh, playing a key role in the core technology team. After working at Medis BV in Leiden,Holland he became software architect at 3mensio BV. On return to the UK, Laurence joined Biotronics3D where he lead the development of their cloud PACS: 3dmetmedical, taking the technology from inception to daily clinical use in over 150 institutions across the EU. He then worked with the InnerEye team at Microsoft Research in Cambridge, bringing his expertise to clinical integration of their AI technologies. Laurence has a wealth of experience leading the transition from research of novel applications into the healthcare domain, delivered to the highest standards required by current regulatory frameworks.


Alex Menys, CEO, said: “I’m incredibly excited to have Laurence onboard and especially at this important transition point for the company where we’re getting ready to take our technology into the clinic. I think we’re both going to learn a lot!”

Laurence Bourn, CTO, said: “The Motilent team have worked extremely hard to develop the technology and crucially the evidence base for MRI in digestive disease. An incredibly important but under served area of need in healthcare. It’s great to join the team at this exciting time as we broaden our clinical portfolio and bring our products to an international audience.”

END-

Certified QMS

Motilent are pleased to announce that we were successful in obtaining ISO:13485:2016 certification from British Standards Institute. This means that our quality management system is to a globally recognised standard for the design, development and distribution of medical imaging analysis software. The QMS forms the backbone of our organisation, ensuring that quality products are developed and improved to meet the complex user needs of the gastrointestinal patient community.

Motilent welcomes Gianni

Motilent would like to welcome aboard our new senior software engineer Gianni Mereu. Gianni holds a PhD in microelectronics and has over 5 years experience as a software developer, specifically working with Javascript for front end applications and Python for the back end. Gianni will be heading up the development of Motilent’s research platform, enabling us to scale to meet the demands of the research community with new solutions and streamlined workflows.